ArticleObesity (Silver Spring, Md.)2019
Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.
Article in Obesity (Silver Spring, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Healthcare Resource Utilisation and Cost of Obesity and Related Complications in the United States: A Systematic Literature Review.Diabetes, obesity & metabolism · 2026Pooled it
- Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Pooled it
- Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity:Saudi medical journal · 2026Article
- Twenty-Four Month Outcomes From a Real-World Telehealth Obesity Treatment Clinic Using Obesity Medications.Obesity (Silver Spring, Md.) · 2026Observational
- Clinical characteristics, treatment patterns, and healthcare utilization among children, adolescents, and young adults with obesity in the United States.Obesity pillars · 2026Article
- Review
- Eating disorder psychopathology relates to weight loss medication and supplement use 6 months later in women.Eating and weight disorders : EWD · 2026Article
- Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey.Journal of racial and ethnic health disparities · 2026Article
- The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics.Contemporary clinical trials · 2026Article
- Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.Pediatric obesity · 2026Observational
- Attitudes towards different weight loss approaches among adults with type 2 diabetes and obesity.Patient education and counseling · 2025Article
- Lower incidence of diabetic retinopathy and worsening events after phentermine assisted weight loss across a large U.S. cohort.Eye (London, England) · 2025Article
- Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers.Scientific reports · 2025Article
- Characterizing obesity: A qualitative study.Obesity pillars · 2025Article
- Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.Lancet (London, England) · 2025Article
- Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025Article
- Therapeutic inertia in obesity management among people living with obesity from the perspective of general/family practitioners in Canada: A mixed-methods study.Clinical obesity · 2025Article
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.JAMA network open · 2025 · on this mapObservational
- Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.Patient preference and adherence · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectiveThe aim of this study was to examine the prescribing patterns and use of antiobesity medications in a large cohort of patients using data from electronic health records.
methodsPharmacy- and patient-level electronic health record data were obtained on 2,248,407 adults eligible for weight-loss medications from eight geographically dispersed health care organizations.
resultsA total of 29,964 patients (1.3% of total cohort) filled at least one weight-loss medication prescription. This cohort was 82.3% female, with median age 44.9 years and median BMI 37.2 kg/m
conclusionsWeight-loss medications are rarely prescribed to eligible patients. Phentermine accounted for > 75% of all medication days, with a majority of patients filling it for more than 4 months. Less than one-quarter of prescribing providers accounted for approximately 90% of all prescriptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.